Recurrent benign fibrous histiocytoma of the bone benefits from denosumab followed by malignant transformation: a case report.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 38374215.
- Also identified by DOI 10.1007/s00256-024-04610-w and PMC identifier 11410898.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Benign fibrous histiocytoma of the bone (BFHB) is a rare mesenchymal tumor, representing less than 1% of all benign bone tumors. This controversial entity is characterized by a mixture of fibroblasts arranged in a storiform pattern, varying amounts of osteoclast-type giant cells and foamy macrophages. Curettage or simple resection is usually curative. However, it was reported that up to 11% of the patients suffer from relapse. Here, we report a case of malignant transformation of BFHB after long-lasting disease stabilization under denosumab therapy.
Medical subject headings
- Denosumab
- Histiocytoma, Benign Fibrous
- Neoplasm Recurrence, Local
- Bone Neoplasms
- Bone Density Conservation Agents